A Vaccine That Struggled Badly at Launch Kenya's current momentum looks very different from where the programme started. When HPV vaccination was rolled out nationally in 2019, following a pilot in Kitui County, the Ministry of Health set a target uptake of 80%. Dr. Rose Jalang'o of the National Vaccines and Immunisation Programme framed the strategy clearly at the time: "Since HPV vaccines are prophylactic, the largest impact of vaccination on the incidence of cervical cancer is expected to result from high coverage of young adolescent girls before first sexual contact." The reality fell far short of that target. By 2020, only 33% of the targeted population had received a first dose, and just 16% returned for the second, a gap researchers have traced to a mix of COVID-19 disruption and, more persistently, misinformation-driven hesitancy: myths linking the vaccine to infertility, unfounded fears about side effects, and concerns among some parents that vaccinating daughters against a sexually transmitted virus would be read as condoning promiscuity. One study in Garissa County found 94.3% of girls in the targeted age group remained unvaccinated, with those same beliefs cited as the dominant barrier. Why Closing That Gap Actually Matters Cervical cancer is the second most common cancer among Kenyan women aged 15 to 44, and it ranks as the leading cause of cancer deaths among Kenyan women overall. HPV accounts for 99.7% of all cervical cancer cases, with two strains, HPV 16 and 18, responsible for more than 70% of them. The same viral family also contributes to a meaningful share of anal, throat, vaginal, vulvar and penile cancers, making the vaccine's public health value broader than cervical cancer prevention alone. Against that backdrop, this year's 69% coverage figure for at least one dose represents genuine, hard-won progress from a programme that spent its first several years significantly underperforming its own targets. A Genuine Success, With a Caveat Attached According to WUENIC data (the WHO/UNICEF Estimates of National Immunization Coverage), approximately 69% of adolescent girls in Kenya have now received at least one HPV vaccine dose. Dr. Shaheen Nilofer, UNICEF's Representative in Kenya, framed the achievement and the gap in the same breath: "Immunisation is every child's right. While we celebrate the success of the expansion of HPV vaccination in Kenya, it also serves as a challenge to redouble our efforts and close the gap to reach 'zero-dose' children." Gavi CEO Dr. Sania Nishtar credited the coordination behind the numbers more broadly: "The historic levels of immunisation that we are seeing across lower income countries shows what can be achieved when all stakeholders work together towards a shared objective." Why "Zero-Dose" Matters More Than a Single Vaccine's Coverage Rate A zero-dose child hasn't just missed HPV protection; they've missed the entire routine immunization schedule, DTP, polio, measles, the full sequence that most Kenyan children receive by their second birthday. Globally, the same report found 7.3 million infants received their first DTP dose but dropped out before their first measles dose, a pattern that has stalled measles coverage worldwide at 84% for the first dose and just 77% for the second, both well short of the 95% threshold needed to prevent outbreaks. That global drop-out pattern contributed to 57 countries reporting large or disruptive measles outbreaks in 2025 alone, underscoring that a rising average coverage rate can coexist with a stagnant, structurally excluded group of children who never enter the system in the first place. The Recent History of Vaccination Campaigns in Kenya Kenya's push on immunization isn't limited to HPV. In July 2025, a ten-day integrated Measles-Rubella and Typhoid Conjugate Vaccine campaign vaccinated over 16 million children across all 47 counties, reaching 16.1 million children for typhoid (84% coverage) and 5.18 million for measles-rubella (81% coverage). That campaign specifically identified and vaccinated 74,000 previously zero-dose children, evidence that targeted, time-bound campaigns can reach populations routine service delivery consistently misses, even if they haven't yet closed the gap entirely. Typhoid alone affects more than 100,000 Kenyans annually, with children under 15 accounting for more than half of all cases and deaths, a burden compounded by the rise of antimicrobial-resistant strains that make treatment both harder and more expensive. What the Numbers Don't Resolve Kenya's routine immunization schedule now includes the Typhoid Conjugate Vaccine at nine months, offering roughly four years of protection with a single dose, alongside the growing HPV rollout. But a rising national average, even one climbing as fast as this year's 80% HPV increase, can mask exactly the same static, hard-to-reach 135,000 children year after year, families in informal settlements, remote pastoral areas, or communities where vaccine hesitancy runs deeper than access alone. Closing that specific gap, rather than continuing to raise the national average around it, is the harder problem Kenya's immunization programme has not yet solved, and the same hesitancy dynamics that suppressed early HPV uptake, distrust built on misinformation rather than access barriers alone, are likely embedded within that remaining zero-dose population too. _Reporting sources: UNICEF Kenya (July 2026); WHO/UNICEF Estimates of National Immunization Coverage (WUENIC); WHO/AFRO; Kenya Ministry of Health; Frontiers in Public Health (Karanja-Chege, 2022); The Elephant; International Journal of Community Medicine and Public Health (Garissa County study)._